Verici Dx expands diagnostics portfolio with Q4 launch of TranscripTx

VRCI

Verici Dx Plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced it will be launching TranscripTx™, a first-in-class genetic test specifically designed for the transplant community, in Q4 2026.

TranscripTx™ is an innovative genetic test designed to identify key variations in a person’s genes that are known to impact biological processes relevant to transplant patients. These variations, known as polymorphisms or genetic variants, can assist in patient management by informing clinicians about the way a transplant recipient may respond to therapy or may help assess their long-term risk of graft failure. This information may help accelerate new drug development, inform ongoing clinical trials, and ultimately, improve medical management protocols.

The test uses next-generation sequencing to measure genetic variants found in peripheral blood RNA. TranscripTx™ will be offered as a laboratory developed test (LDT) in Verici’s CLIA-certified, CAP accredited laboratory.

TranscripTx™ incorporates AI-enabled evidence-based gene selection specifically tailored to transplant. The genes are backed by peer-reviewed literature1 to provide clinically meaningful insights, and it is the only multi-gene panel developed specifically for transplant recipients. Leveraging Verici’s deep expertise in RNA diagnostics, the test will also be capable of detecting clinically-relevant genetic splice variants that are impossible to detect using cell-free DNA technologies.

TranscripTx™ demonstrates the strategic value of Verici’s extensive repository of clinical data and biological samples to rapidly perform retrospective analyses and commercialise new diagnostic products.

1 Nobakht E, Jagadeesan M, Paul R, Bromberg J, Dadgar S. Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope? Transplant Direct. 2021 Jan 7;7(2):e650. doi: 10.1097/TXD.0000000000001102. PMID: 33437865; PMCID: PMC7793397.

Sara Barrington, CEO of Verici Dx, commented: “With TranscripTx™, we are translating cutting-edge RNA science into actionable intelligence and providing the research community with an unprecedented level of biological insight. This launch translates our robust data repository into a tangible, multi-gene asset that will push the boundaries of precision medicine. This test underscores our commitment to pioneering personalised diagnostics in transplantation, maximising the strategic value of our clinical data while offering a vital new resource for therapeutic development and patient care.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Verici Dx secures Asahi Kasei Therapeutics order for phase 2 transplant trial

Verici Dx will provide blood-based biomarker testing, including its Pre-Transplant Risk Assessment assay, for a Phase 2 clinical trial...

Search